文献速递前列腺癌

一项前瞻性随机试验:比较减低剂量与标准剂量恩扎卢胺对体弱前列腺癌患者副作用的影响

A Prospective Randomised Trial to Determine the Effect of a Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2024-03-13

这项多中心随机试验在体弱前列腺癌患者中比较恩扎卢胺标准剂量160 mg每日一次与减低剂量120 mg每日一次的副作用。共52例患者纳入分析(减低剂量组25例,标准剂量组27例)。减低剂量组治疗24周后疲乏显著低于标准剂量组(FACIT-疲乏评分差异6.2;95%CI 1.4-11.0;p=0.01),且随时间维持稳定,而标准剂量组24周后疲乏、认知副作用和抑郁症状较基线显著恶化。

要点

  • 体弱前列腺癌患者减低剂量恩扎卢胺120 mg每日一次较标准剂量160 mg每日一次疲乏显著更低。
  • 减低剂量组疲乏、认知副作用和抑郁症状随时间稳定,标准剂量组24周后较基线显著恶化。
  • 减低剂量未见影响疗效终点的迹象。

核心结论

  • 在体弱前列腺癌患者中,减低剂量恩扎卢胺较标准剂量引起更少的疲乏、认知副作用和抑郁症状,且无任何影响疗效终点的迹象。

研究设计与样本

  • 多中心随机试验,比较恩扎卢胺标准剂量160 mg每日一次与减低剂量120 mg每日一次,纳入体弱前列腺癌患者,共52例纳入分析(减低剂量组25例,标准剂量组27例)。

主要发现

  • 减低剂量组治疗24周后疲乏显著低于标准剂量组(FACIT-疲乏评分差异6.2;95%CI 1.4-11.0;p=0.01)。
  • 减低剂量组随时间疲乏、认知副作用和抑郁症状保持稳定,而标准剂量组24周后较基线显著恶化。

关键数值与推荐

  • 疲乏采用FACIT-疲乏问卷评估,认知副作用采用FACT-Cog问卷评估,抑郁症状采用GDS-15评估。
  • 采用线性混合效应模型研究两组副作用随时间的变化差异。

临床怎么用

  • 减低剂量恩扎卢胺(120 mg每日一次)可用于减轻体弱前列腺癌患者的副作用,且无疗效降低的迹象。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Enzalutamide is a potent androgen receptor signalling inhibitor, effectively used for the treatment of different stages of prostate cancer. Side effects occur frequently at the registered dose, whilst a lower dose might be equally effective. Therefore, the aim of this study is to determine the effect of a reduced dose of enzalutamide on side effects in frail patients with prostate cancer. METHODS: This multicentre randomised trial compared the standard enzalutamide dose of 160 mg once daily (OD) with a reduced dose of 120 mg OD in frail patients with prostate cancer. Fatigue, cognitive side effects, and depressive symptoms were measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) questionnaire, Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) questionnaire, and Geriatric Depression Scale-15 (GDS-15). Linear mixed-effect models were used to study differences in side effects over time between both groups. KEY FINDINGS AND LIMITATIONS: In total, 52 patients were included in the analysis (25 reduced dose and 27 standard dose). Patients treated with the reduced dose had significantly lower fatigue after 24 wk than those with the standard dose (difference FACIT-Fatigue 6.2; 95% confidence interval 1.4-11.0; p = 0.01). Patients treated with the reduced dose showed stable fatigue, cognitive side effects, and depressive symptoms over time, whilst patients with the standard dose showed significantly worse side effects after 24 wk than at baseline. CONCLUSIONS AND CLINICAL IMPLICATIONS: A reduced dose of enzalutamide results in less fatigue, cognitive side effects, and depressive symptoms in frail patients with prostate cancer than the standard dose, without any indication of interference with efficacy endpoints. PATIENT SUMMARY: In this report, we looked at the side effects of enzalutamide at two dose levels. We found that, in frail patients, three tablets a day result in less fatigue than four tablets a day. Patients treated with four tablets a day showed an increase in fatigue, cognitive side effects, and depression. We conclude that a lower dose of three tablets can be used to alleviate side effects without indications for less efficacy.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Boerrigter E, Overbeek JK, Benoist GE, et al. A Prospective Randomised Trial to Determine the Effect of a Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer. Eur Urol Oncol. 2024. PMID: 38485614. doi:10.1016/j.euo.2024.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。